You are here

Share:

Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation

Summary
The National Eye Institute's Ophthalmic Genetics and Visual Function Branch seeks interested commercial parties to co-develop the use of nitisinone (NTBC) for oculocutaneous albinism or as a treatment for increasing pigmentation in the eyes, hair and/or skin of patients.
NIH Reference Number
E-113-2010
Product Type
Keywords
  • Ocular disorders
  • Albinism
  • Pigmentation
  • Nitisinone
  • achromia, achromasia, achromatosis
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

Albinism (also called achromia, achromasia, or achromatosis) is a congenital disorder characterized by the complete or partial absence of pigment in the skin, hair and eyes due to absence or defect in any one of a number of proteins involved in the production of melanin.  Certain forms of albinism are known to be due to mutations in tyrosine metabolism.  In oculocutaneous albinism (OCA), pigment is lacking in the eyes, skin and hair.  In ocular albinism, only the eyes lack pigment.  Patients with albinism experience varying degrees of vision loss associated with foveal hypoplasia, nystagmus, photophobia and/or glare sensitivity, refractive errors, and abnormal decussation of ganglion cell axons at the optic chiasm.  Current treatment options for vision problems caused by albinism are limited to correction of refractive errors and amblyopia, low vision aids, and (in some cases) extraocular muscle surgery.

Nitisinone (NTBC) is an FDA-approved drug used in the treatment of tyrosinemia, type 1.  The drug blocks the normal degradation pathway of tyrosine thus allowing greater circulating plasma levels of tyrosine.  NEI investigators identified administration of NTBC to subjects (e.g., mice or humans) with certain forms of albinism, can result in increased circulating tyrosine levels, an increase in tyrosinase activity, and, subsequently, increased pigmentation. Co-development research agreements with companies are sought to advance this treatment to humans.

Potential Commercial Applications
  • Nitisinone (NTBC) is an FDA-approved drug used in the treatment of tyrosinemia, type 1
Competitive Advantages
  • Nitisinone (NTBC) is an FDA-approved drug used in the treatment of tyrosinemia, type 1
Inventor(s)
Development Stage
Publications

Adams DR et al. One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B. JCI Insight. 2019 Jan 24;4(2):e124387. doi: 10.1172/jci.insight.124387. Epub ahead of print. [PMID: 30674731]

Brooks, B.P. Nitisinone for Type 1B Oculocutaneous Albinism.  ClinicalTrials.gov Identifier: NCT01838655

Patent Status
  • U.S. Patent Issued: U.S. Patent Number 8822540, Filed 06 Sep 2012, Issued 02 Sep 2014
  • Foreign Filed: Foreign Filed - Patent Application WO 02011106655
  • Foreign Issued: - Patent Number 2791245, Filed 25 Feb 2011, Issued 15 Jan 2019
  • Foreign Issued: EP - Patent Number 2538936, Filed 25 Feb 2011, Issued 24 Dec 2014
  • Foreign Issued: Australia - Patent Number 2011220475, Filed 25 Feb 2011, Issued 10 Jul 2014
Therapeutic Area
Updated
Tuesday, June 8, 2021